6,7,4′-Trihydroxyisoflavone inhibits HCT-116 human colon cancer cell proliferation by targeting CDK1 and CDK2

Cited 43 time in scopus
Metadata Downloads

Full metadata record

DC FieldValueLanguage
dc.contributor.authorD E Lee-
dc.contributor.authorK W Lee-
dc.contributor.authorS K Jung-
dc.contributor.authorE J Lee-
dc.contributor.authorJ A Hwang-
dc.contributor.authorT G Lim-
dc.contributor.authorBo Yeon Kim-
dc.contributor.authorA M Bode-
dc.contributor.authorH J Lee-
dc.contributor.authorZ Dong-
dc.date.accessioned2017-04-19T09:22:24Z-
dc.date.available2017-04-19T09:22:24Z-
dc.date.issued2011-
dc.identifier.issn0143-3334-
dc.identifier.uri10.1093/carcin/bgr008ko
dc.identifier.urihttps://oak.kribb.re.kr/handle/201005/10087-
dc.description.abstractColon cancer is a common epithelial malignancies worldwide. Epidemiologic evidence has shown that nutrition and dietary components are important environmental factors involved in the development of this disease. We investigated the biological activity of 6,7,4'-trihydroxyisoflavone (6,7,4'-THIF, a metabolite of daidzein) in in vitro and in vivo models of human colon cancer. 6,7,4'-THIF suppressed anchorage-dependent and -independent growth of HCT-116 and DLD1 human colon cancer cells more effectively than daidzein. In addition, 6,7,4'-THIF induced cell cycle arrest at the S and G2/M phases in HCT-116 human colon cancer cells. Western blot analysis revealed that 6,7,4'-THIF effectively suppressed the expression of cyclin-dependent kinase (CDK) 2, but had no effect on other S- or G2/M-phase regulatory proteins such as cyclin A, cyclin B1 or CDK1. Daidzein did not affect the expression of any of these proteins. In kinase and pull-down assays, 6,7,4'-THIF, but not daidzein, inhibited CDK1 and CDK2 activities in HCT-116 cells by directly interacting with CDK1 and CDK2. In a xenograft mouse model, 6,7,4'-THIF significantly decreased tumor growth, volume and weight of HCT-116 xenografts. 6,7,4'-THIF bound directly to CDK1 and CDK2 in vivo, resulting in the suppression of CDK1 and CDK2 activity in tumors corresponding with our in vitro results. Collectively, these results suggest that CDK1 and CDK2 are potential molecular targets of 6,7,4'-THIF to suppress HCT-116 cell proliferation in vitro and in vivo. These findings provide insight into the biological actions of 6,7,4'-THIF and might establish a molecular basis for the development of new cancer therapeutic agents.-
dc.publisherOxford Univ Press-
dc.title6,7,4′-Trihydroxyisoflavone inhibits HCT-116 human colon cancer cell proliferation by targeting CDK1 and CDK2-
dc.title.alternative6,7,4′-Trihydroxyisoflavone inhibits HCT-116 human colon cancer cell proliferation by targeting CDK1 and CDK2-
dc.typeArticle-
dc.citation.titleCarcinogenesis-
dc.citation.number4-
dc.citation.endPage635-
dc.citation.startPage629-
dc.citation.volume32-
dc.contributor.affiliatedAuthorBo Yeon Kim-
dc.contributor.alternativeName이동은-
dc.contributor.alternativeName이기원-
dc.contributor.alternativeName정성근-
dc.contributor.alternativeName이은정-
dc.contributor.alternativeName황정아-
dc.contributor.alternativeName임태규-
dc.contributor.alternativeName김보연-
dc.contributor.alternativeNameBode-
dc.contributor.alternativeName이형주-
dc.contributor.alternativeNameDong-
dc.identifier.bibliographicCitationCarcinogenesis, vol. 32, no. 4, pp. 629-635-
dc.identifier.doi10.1093/carcin/bgr008-
dc.description.journalClassY-
Appears in Collections:
Ochang Branch Institute > Chemical Biology Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.